Mumbai-based Ipca Laboratories has received approval for its Anti-malarial (finished fixed dose) combination formulation - Artemether and Lumefantrine under World Health Organisation's pre-qualification programme.
In a statement to the Bombay Stock Exchange, the company said that this makes lpca Labs the fourth company in the world to have pre-qualification for this product.
The list of pre-qualified medicinal products is used principally by United Nations agencies including UNAIDS and UNICEF- to guide their procurement decisions.
The pre-qualification programme was created by WHO in 2001 to increase access to priority medicinal products that meet unified standards of acceptable quality, safely and efficacy, currently focusing on those medicines used for treatment of diseases such as malaria.
The company's scrip was trading at Rs 993, up 2.07 per cent on the BSE.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app